GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (STU:G51) » Definitions » EPS (Diluted)

Genscript Biotech (STU:G51) EPS (Diluted) : €-0.04 (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Genscript Biotech EPS (Diluted)?

Genscript Biotech's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was €-0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.04.

Genscript Biotech's EPS (Basic) for the six months ended in Dec. 2023 was €-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.04.

Genscript Biotech's EPS without NRI for the six months ended in Dec. 2023 was €-0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.05.

During the past 3 years, the average EPS without NRIGrowth Rate was 20.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, Genscript Biotech's highest 3-Year average EPS without NRI Growth Rate was 56.50% per year. The lowest was -28.80% per year. And the median was 14.20% per year.


Genscript Biotech EPS (Diluted) Historical Data

The historical data trend for Genscript Biotech's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech EPS (Diluted) Chart

Genscript Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.09 -0.16 -0.10 -0.04

Genscript Biotech Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.06 -0.04 -0.04 -

Competitive Comparison of Genscript Biotech's EPS (Diluted)

For the Biotechnology subindustry, Genscript Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genscript Biotech's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's PE Ratio distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's PE Ratio falls into.



Genscript Biotech EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Genscript Biotech's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-87.552-0)/2109.365
=-0.04

Genscript Biotech's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.739-0)/2111.849
=-0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genscript Biotech  (STU:G51) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Genscript Biotech EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Genscript Biotech (STU:G51) Business Description

Traded in Other Exchanges
Address
No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100
GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.

Genscript Biotech (STU:G51) Headlines

No Headlines